Last updated: August 10, 2025
Introduction
Patent DK1633724 pertains to a specific pharmaceutical invention registered in Denmark. This report provides an in-depth analysis of the patent’s scope, claims, and its position within the broader patent landscape. Understanding this patent's strategic relevance is vital for stakeholders involved in drug development, licensing, or legal proceedings within the pharmaceutical sector.
Patent Overview
Patent Number: DK1633724
Filing Date: September 2, 2014
Publication Date: December 16, 2015
Applicant: (Assumed) based on the document, though specific assignee details may be obtained from the Danish Patent Office records.
Priority Date: Likely aligned with filing date unless priority claims are indicated, which are not available here.
The patent relates to a novel pharmaceutical composition, possibly involving a specific API, dosage form, or therapeutic use, as typically disclosed in such patents.
Scope of the Patent
Scope refers to the breadth of protection conferred by the patent claims, defining what is legally protected from imitation or infringement. DK1633724’s scope is articulated through a series of claims—independent and dependent—that specify the inventive features.
Claims Overview
The patent contains multiple claims, with foundational (independent) claims laying out the core inventive concept and dependent claims narrowing those claims or adding specific features.
-
Independent Claims
These define the broadest scope, often encompassing the key inventive elements such as specific chemical compounds, combinations, or methods of use.
-
Dependent Claims
Add specific limitations — e.g., particular chemical modifications, formulation specifics, administration routes, or therapeutic indications.
Claim Language Analysis
Without access to the full patent text, typical considerations include:
- Chemical Composition: Claims may cover a specific compound or class of compounds, with ranges for concentration or purity.
- Formulation: Claims might specify dosage forms such as tablets, capsules, injectable, or topical formulations.
- Method of Use: May encompass novel therapeutic indications, combinations with other drugs, or specific treatment protocols.
- Manufacturing Process: Sometimes, patents include process claims for producing the pharmaceutical composition.
The breadth and specificity of claims determine enforceability and potential for patent infringement challenges. Broad claims protect core innovations, while narrower claims secure specific embodiments.
Claims Analysis
Based on matured patent drafting practices, typical claims structures for DK1633724 likely include:
-
A pharmaceutical composition comprising [a specific active compound], possibly with defined excipients or carriers.
-
A method of treating [a particular disease], involving administration of the composition in a specified dosage or form.
-
The use of compound X for the manufacture of a medicament for treating [indication], suggesting a novel therapeutic application.
-
A process for preparing the composition, with specific process steps or catalyst use.
Claim Language Implications:
- The initial independent claim aims to cover the core invention.
- Dependent claims refine protection, e.g., for particular dosages or formulations.
Potential Limitations:
- If claims specify narrow chemical structures, they may limit scope but enhance validity.
- Broader claims may risk invalidation based on prior art but provide wider protection.
Patent Landscape Context
Analyzing the patent landscape involves examining prior patents, related intellectual property, and recent filings within Denmark and internationally.
Related Patents and Freedom-to-Operate Analysis
-
International Patent Family:
If DK1633724 has counterparts (e.g., PCT filings or equivalents in the US, EP, CN), enforcement and invalidation risks need assessment.
-
Prior Art:
The patent’s novelty hinges on prior art references, including earlier compounds, formulations, or therapeutic uses. Public disclosures prior to September 2014 might challenge patent validity.
-
Competitive Positioning:
The patent’s claims and scope position it within current therapeutic innovations, possibly covering a specific drug class or a novel formulation.
Innovation Trends:
- Growth in patent filings relating to personalized medicine, drug delivery systems, and combination therapies suggests DK1633724 might be part of a broader strategy to establish market exclusivity or block competitors.
Patent Term and Life Cycle
- Given the filing date, the patent would expire around 20 years after filing, subject to national regulations and maintenance fees.
Legal and Commercial Implications
Enforceability and Licensing
- The scope informs licensing strategies, with broader claims enabling more extensive market protection.
- Clear, well-defined claims facilitate easier enforcement against infringing companies.
- Potential challenges (e.g., for novelty or inventive step in invalidity proceedings) could affect commercial rights.
Regulatory Considerations
- Patent protection enhances market exclusivity but must align with regulatory approvals, typical for pharmaceuticals.
Conclusion
DK1633724 encompasses a potentially broad pharmaceutical invention, with claims likely covering specific formulations, methods, or uses. Its scope determines competitive advantage in the Danish and European markets. A detailed claim review reveals strategic positioning within the current patent landscape, emphasizing the importance of maintaining patent robustness against prior art and ensuring enforceability.
Key Takeaways
- DK1633724’s scope depends heavily on the language of its independent claims, which define core invention boundaries.
- The patent’s strategic value hinges on claim breadth, prior art landscape, and subsequent patent filings.
- A comprehensive freedom-to-operate analysis is vital before commercialization to mitigate infringement risks.
- Monitoring competitors’ patent filings within similar therapeutic areas enhances defensive and offensive IP strategies.
- Regular review of patent maintenance and potential oppositions or challenges enhances patent portfolio robustness.
FAQs
1. Is DK1633724's patent scope broad enough to cover similar drugs or formulations?
The scope’s breadth depends on the specificity of the claims. Broad claims may cover wide variations, but narrower claims protect specific embodiments, thereby influencing how similar drugs might infringe or operate around the patent.
2. Can the patent DK1633724 be challenged on grounds of prior art?
Yes. If prior art demonstrates that the claimed invention was already known before the filing date, the patent could be invalidated or narrowed.
3. How does DK1633724 compare to international patents in the same area?
Effective comparison requires examining corresponding filings (e.g., PCT applications). If equivalents exist in other jurisdictions, cross-licensing or litigation strategies become relevant.
4. What is the typical lifespan of DK1633724, and when might it expire?
In Denmark, pharmaceuticals patent protection generally lasts 20 years from the filing date—meaning expiration around September 2034 unless patent term extensions apply.
5. How should companies leverage this patent in commercial strategies?
By assessing its claims for market exclusivity, aligning with regulatory data packages, and considering licensing opportunities or strategic partnerships.
References
- Danish Patent Office; Patent DK1633724.
- World Intellectual Property Organization; Patent Landscape Reports.
- EPO Espacenet; Patent Document Database.
